Reduction of at least 4 points in SELENA‐SLEDAI at 52 weeks SELENA‐SLEDAI score, a validated marker of SLE disease activity (range 0 to 105; higher score = worse disease activity) · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)
Belimumab 10 mg/kg leads to higher reduction of at least 4 points in SELENA‐SLEDAI at 52 weeks… compared with placebo (high certainty).
1 finding from 1 review
Change in HRQOL, on SF‐36 PCS score at 52 weeks Improvement in SF‐36 PCS score from baseline ( · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)
Belimumab 10 mg/kg probably leads to higher change in HRQOL, on SF‐36 PCS score at 52 weeks Improvement in SF‐36… compared with placebo (moderate certainty).
1 finding from 1 review
Reduction of glucocorticoid dose by at least 50% · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)
Belimumab 10 mg/kg leads to higher reduction of glucocorticoid dose by at least 50% compared with placebo (high certainty).
1 finding from 1 review
Participants with one or more serious adverse events · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)
Belimumab 10 mg/kg showed no clear difference in participants with one or more serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Participants with one or more serious infections · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)
Belimumab 10 mg/kg showed no clear difference in participants with one or more serious infections compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)
Belimumab 10 mg/kg showed no clear difference in withdrawals due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Number of participants who died during the study · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)
Belimumab 10 mg/kg showed no clear difference in number of participants who died during the study compared with placebo (low certainty).
1 finding from 1 review
Pain (VAS, PRTEE) translated to 0 to 10, where 0 is no pain · lateral elbow pain
1 finding from 1 review
Disability DASH scale. Scale from: 0 to 100. ( · lateral elbow pain
1 finding from 1 review
Treatment success (> 25% improvement in pain or function) · lateral elbow pain
It is very uncertain whether autologous blood or PRP changes treatment success (> 25% improvement in pain or function) compared with placebo at 3 months' follow‐up (very low certainty).
1 finding from 1 review
Health‐related Quality of Life Not measured · lateral elbow pain
1 finding from 1 review
Relief of pain · lateral elbow pain
1 finding from 1 review
Withdrawals due to adverse events · lateral elbow pain
It is very uncertain whether autologous blood or PRP changes withdrawal due to adverse events  compared with placebo at 3 months' follow‐up (very low certainty).
1 finding from 1 review
Adverse events (pain and swelling at injection site and limitation of elbow movement following injection) · lateral elbow pain
Autologous blood or PRP showed no clear difference in adverse events (pain and swelling at injection site and limitation… compared with placebo at 3 months' follow‐up (low certainty).
1 finding from 1 review
Relief of overall pain ‐ reported as pelvic pain ‐ 3 months · women with endometriosis, following complete surgical excision of lesions
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events ‐ pelvic pain · women with endometriosis, following complete surgical excision of lesions
It is very uncertain whether raloxifene changes adverse events ‐ pelvic pain compared with placebo (very low certainty).
1 finding from 1 review
Adverse events ‐ ovarian cyst · women with endometriosis, following complete surgical excision of lesions
It is very uncertain whether raloxifene changes adverse events ‐ ovarian cyst compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects: headache · women with endometriosis, following complete surgical excision of lesions
It is very uncertain whether raloxifene changes adverse events ‐ headache compared with placebo (very low certainty).
1 finding from 1 review
Adverse events ‐ migraine · women with endometriosis, following complete surgical excision of lesions
It is very uncertain whether raloxifene changes adverse events ‐ migraine compared with placebo (very low certainty).
1 finding from 1 review
Adverse events ‐ depression · women with endometriosis, following complete surgical excision of lesions
It is very uncertain whether raloxifene changes adverse events ‐ depression compared with placebo (very low certainty).
1 finding from 1 review